Advertisement

Topics

Samsung Bioepis and Takeda Collaborate for Development of Multiple Novel Biologic Therapies

09:24 EDT 21 Aug 2017 | Speciality Pharma Journal

INCHEON, Korea–(BUSINESS WIRE)–Samsung Bioepis Co., Ltd. announced today that it has entered into a strategic collaboration agreement with Takeda Pharmaceutical Company Limited (TSE: 4502) to jointly fund and co-develop multiple novel biologic therapies in unmet disease areas. The two companies will immediately begin working on the program’s first therapeutic candidate, TAK-671, which is intended to …

Original Article: Samsung Bioepis and Takeda Collaborate for Development of Multiple Novel Biologic Therapies

NEXT ARTICLE

More From BioPortfolio on "Samsung Bioepis and Takeda Collaborate for Development of Multiple Novel Biologic Therapies"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...